Clinical Trial

Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML

Study acronym: CHANCE
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial tests how well VA alternating with low-dose CHA works in treating unfit patients with newly diagnosed acute myeloid leukemia (AML). This is a prospective, multi-centers, single arm phase II study aimed to overcome VEN resistance and achieve greater MRD negative rate, providing better control of treatment for unfit AML.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-07; most recent amendment 2026-02-02.
Trial Details
NCT Number NCT07172204
Lead Sponsor First Affiliated Hospital of Zhejiang University
Collaborators: AbbVie
Conditions Intensive Chemotherapy Unfit, Newly Diagnosed Acute Myeloid Leukemia (AML), Age ≥60
Enrollment 25 participants
Start Date 2025-09-16
Primary Completion 2027-07-31 (estimated)
Study Completion 2029-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-04